Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. Ooki · SciRah

Researcher profile · Semantic Scholar

A. Ooki

Share profile

A. Ooki — researcher profile on SciRah

h-index: 19
Works: 117
Citations: 1,209

Most-cited papers

Immunotherapy in Colorectal Cancer: Current and Future Strategies
A. Ooki, E. Shinozaki, K. Yamaguchi
2021Journal of the Anus Rectum and Colon89 citations Open access
Semantic Scholar
Potent therapeutic strategy in gastric cancer with microsatellite instability-high and/or deficient mismatch repair
A. Ooki, H. Osumi, K. Yoshino, Kensei Yamaguchi
2024Gastric Cancer56 citations Open access
Semantic Scholar
The dawn of precision medicine in diffuse-type gastric cancer
A. Ooki, K. Yamaguchi
2022Therapeutic Advances in Medical Oncology46 citations Open access
Semantic Scholar
HER2-low gastric cancer: is the subgroup targetable?
K. Shimozaki, S. Fukuoka, A. Ooki, K. Yamaguchi
2024ESMO Open37 citations Open access
Semantic Scholar
GULP1 regulates the NRF2-KEAP1 signaling axis in urothelial carcinoma
Masamichi Hayashi, Elisa Guida, Yoshikuni Inokawa, Rachel Goldberg +17 more
2020Science Signaling35 citations
Semantic Scholar
The beginning of the era of precision medicine for gastric cancer with fibroblast growth factor receptor 2 aberration
A. Ooki, K. Yamaguchi
2021Gastric Cancer27 citations Open access
Semantic Scholar
Neoadjuvant Chemoradiotherapy with Cisplatin Plus Fluorouracil for Borderline Resectable Esophageal Squamous Cell Carcinoma
Takeshi Suzuki, A. Okamura, Masayuki Watanabe, S. Mine +10 more
2019Annals of Surgical Oncology27 citations
Semantic Scholar
Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma
A. Ooki, H. Osumi, K. Chin, Masayuki Watanabe +1 more
2023Therapeutic Advances in Medical Oncology25 citations Open access
Semantic Scholar
Potent molecular-targeted therapies for gastro-entero-pancreatic neuroendocrine carcinoma
A. Ooki, H. Osumi, K. Fukuda, K. Yamaguchi
2023Cancer Metastasis Review23 citations Open access
Semantic Scholar
Non‐V600E BRAF mutations and EGFR signaling pathway in colorectal cancer
H. Osumi, E. Shinozaki, T. Wakatsuki, M. Suenaga +10 more
2019International Journal of Cancer23 citations Open access
Semantic Scholar
Managing zolbetuximab-induced nausea and vomiting: a proposal for a pragmatic approach in clinical practice
K. Shimozaki, A. Ooki, Y. Yamahata, T. Aoyama +10 more
2025ESMO gastrointestinal oncology21 citations Open access
Semantic Scholar
Incidence, clinicopathological features, and clinical outcomes of low HER2 expressed, inoperable, advanced, or recurrent gastric/gastroesophageal junction adenocarcinoma
I. Nakayama, D. Takahari, K. Chin, T. Wakatsuki +9 more
2023ESMO Open20 citations Open access
Semantic Scholar
A multi-institutional observational study evaluating the incidence and the clinicopathological characteristics of NeoRAS wild-type metastatic colorectal cancer
H. Osumi, A. Takashima, A. Ooki, Yuri Yoshinari +17 more
2023Translational Oncology19 citations Open access
Semantic Scholar
Correlation between circulating tumor DNA and carcinoembryonic antigen levels in patients with metastatic colorectal cancer
H. Osumi, E. Shinozaki, A. Ooki, K. Shimozaki +7 more
2021Cancer Medicine19 citations Open access
Semantic Scholar
Novel immunotherapy for gastric cancer: targeting the CD47–SIRPα axis
A. Ooki, H. Osumi, K. Shimozaki, Kensei Yamaguchi
2025Cancer Metastasis Review18 citations
Semantic Scholar
Effect of neutropenia on survival outcomes of patients with metastatic colorectal cancer receiving trifluridine/tipiracil plus bevacizumab
D. Kamiimabeppu, H. Osumi, E. Shinozaki, A. Ooki +8 more
2021Oncology Letters16 citations Open access
Semantic Scholar
KRAS mutation as a predictor of insufficient trastuzumab efficacy and poor prognosis in HER2-positive advanced gastric cancer
K. Shimozaki, E. Shinozaki, N. Yamamoto, Y. Imamura +9 more
2022Journal of Cancer Research and Clinical Oncology15 citations Open access
Semantic Scholar
Circulating Tumor DNA: The Dawn of a New Era in the Optimization of Chemotherapeutic Strategies for Metastatic Colo-Rectal Cancer Focusing on RAS Mutation
Shohei Udagawa, A. Ooki, E. Shinozaki, K. Fukuda +2 more
2023Cancers14 citations Open access
Semantic Scholar
A novel clinical prognostic index for patients with advanced gastric cancer: possible contribution to the continuum of care
K. Shimozaki, I. Nakayama, D. Takahari, D. Kamiimabeppu +7 more
2021ESMO Open13 citations Open access
Semantic Scholar
Associations among plasma concentrations of regorafenib and its metabolites, adverse events, and ABCG2 polymorphisms in patients with metastatic colorectal cancers
K. Kobayashi, E. Sugiyama, E. Shinozaki, T. Wakatsuki +21 more
2021Cancer Chemotherapy and Pharmacology13 citations
Semantic Scholar
Early hypertension and neutropenia are predictors of treatment efficacy in metastatic colorectal cancer patients administered FOLFIRI and vascular endothelial growth factor inhibitors as second‐line chemotherapy
H. Osumi, E. Shinozaki, A. Ooki, T. Wakatsuki +7 more
2020Cancer Medicine13 citations Open access
Semantic Scholar
Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer
Takeshi Suzuki, E. Shinozaki, H. Osumi, I. Nakayama +9 more
2019Cancer Chemotherapy and Pharmacology13 citations
Semantic Scholar
Clinical Usefulness of Postoperative Serum Carcinoembryonic Antigen in Patients with Colorectal Cancer with Liver Metastases
K. Yoshino, H. Osumi, Hiromichi Ito, D. Kamiimabeppu +14 more
2022Annals of Surgical Oncology12 citations
Semantic Scholar
Managing a gastrointestinal oncology practice in Japan during the COVID-19 pandemic: single institutional experience in The Cancer Institute Hospital of Japanese Foundation for Cancer Research
D. Takahari, E. Shinozaki, T. Wakatsuki, A. Ooki +10 more
2020International Journal of Clinical Oncology11 citations Open access
Semantic Scholar
A phase 1b study of andecaliximab in combination with S-1 plus platinum in Japanese patients with gastric adenocarcinoma
A. Ooki, T. Satoh, K. Muro, A. Takashima +12 more
2022Scientific Reports10 citations Open access
Semantic Scholar
Clinical Impact of Primary Tumor Location and RAS, BRAF V600E, and PIK3CA Mutations on Epidermal Growth Factor Receptor Inhibitor Efficacy as Third-line Chemotherapy for Metastatic Colorectal Cancer
Taro Sato, H. Osumi, E. Shinozaki, A. Ooki +8 more
2021Anticancer Research10 citations Open access
Semantic Scholar
Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study
Y. Kitagawa, H. Osumi, E. Shinozaki, Y. Ota +9 more
2020BMC Cancer10 citations Open access
Semantic Scholar
Effect of DNA methylation status on first-line anti-epidermal growth factor receptor treatment in patients with metastatic colorectal cancer
H. Osumi, K. Ouchi, E. Shinozaki, S. Takahashi +8 more
2022International Journal of Colorectal Disease9 citations
Semantic Scholar
Hypoalbuminemia during zolbetuximab plus chemotherapy for claudin 18.2-positive advanced gastric cancer: a need for caution?
K. Shimozaki, A. Ooki, S. Fukuoka, T. Hirasawa +11 more
2025ESMO Gastrointestinal Oncology8 citations Open access
Semantic Scholar
Clinical Progress in Inoperable or Recurrent Advanced Gastric Cancer Treatment from 1004 Single Institute Experiences Between 2007 and 2018
I. Nakayama, D. Takahari, K. Shimozaki, K. Chin +7 more
2022The Oncologist8 citations Open access
Semantic Scholar
Impact of early tumor shrinkage on quality of life in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: results of Phase II QUACK trial
A. Ooki, S. Morita, A. Tsuji, S. Iwamoto +16 more
2022BMC Cancer8 citations Open access
Semantic Scholar
Patient‐reported symptom burden as a prognostic factor in treatment with first‐line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial
A. Ooki, S. Morita, S. Iwamoto, H. Hara +16 more
2020Cancer Medicine8 citations Open access
Semantic Scholar
Disagreement between patient‐ and physician‐reported outcomes on symptomatic adverse events as poor prognosis in patients treated with first‐line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial
A. Ooki, S. Morita, A. Tsuji, S. Iwamoto +16 more
2020Cancer Medicine8 citations Open access
Semantic Scholar
Artificial Intelligence in Clinical Oncology: From Productivity Enhancement to Creative Discovery
Masahiro Kuno, H. Osumi, Shohei Udagawa, K. Yoshikawa +6 more
2025Current Oncology7 citations Open access
Semantic Scholar
Efficacy of anti-epidermal growth factor antibody rechallenge in RAS/BRAF wild-type metastatic colorectal cancer: a multi-institutional observational study
K. Fukuda, H. Osumi, Y. Yoshinami, A. Ooki +17 more
2024Journal of Cancer Research and Clinical Oncology7 citations Open access
Semantic Scholar
Treatment efficacy of ramucirumab-containing chemotherapy in patients with alpha-fetoprotein producing gastric cancer
D. Kamiimabeppu, T. Wakatsuki, D. Takahari, N. Fukuda +8 more
2022International Journal of Clinical Oncology7 citations
Semantic Scholar
Single-institute comparison of the efficacy of systemic chemotherapy for oesophagogastric junction adenocarcinoma and stomach adenocarscinoma in a metastatic setting
I. Nakayama, D. Takahari, T. Wakatsuki, H. Osumi +9 more
2020ESMO Open7 citations Open access
Semantic Scholar
Clinical relevance of circulating tumor DNA in HER2-positive advanced gastric cancer: a collaborative study of a phase Ib trial of dual HER2 and PD-1 targeted therapy (Ni-High)
H. Osumi, T. Wakatsuki, A. Ooki, K. Chin +15 more
2025Therapeutic Advances in Medical Oncology6 citations Open access
Semantic Scholar
Safety and efficacy of first-line nivolumab plus chemotherapy for HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: real-world data analysis
K. Shimozaki, K. Fukuda, A. Ooki, I. Nakayama +11 more
2024ESMO gastrointestinal oncology6 citations Open access
Semantic Scholar
A multicenter randomized open-label phase 2 study investigating optimal antiemetic therapy for patients with advanced/recurrent gastric cancer treated with trastuzumab deruxtecan: the EN-hance study
Toru Aoyama, A. Ooki, Koji Oba, Kazuhiro Nishikawa +14 more
2025International Journal of Clinical Oncology5 citations Open access
Semantic Scholar
Phase I study of pevonedistat combined with capecitabine and oxaliplatin in patients with platinum-refractory advanced gastric cancer
H. Shoji, D. Takahari, A. Ooki, H. Hirano +6 more
2025Scientific Reports5 citations Open access
Semantic Scholar
Efficacy and Safety of Trastuzumab Deruxtecan and Nivolumab as Third- or Later-Line Treatment for HER2-Positive Advanced Gastric Cancer: A Single-Institution Retrospective Study
K. Shimozaki, I. Nakayama, D. Takahari, Kengo Nagashima +10 more
2023Journal of Gastric Cancer5 citations Open access
Semantic Scholar
Safety and efficacy of amrubicin monotherapy in patients with platinum-refractory metastatic neuroendocrine carcinoma of the gastrointestinal tract: a single cancer center retrospective study
Y. Kitagawa, H. Osumi, E. Shinozaki, Y. Ota +10 more
2019Cancer Management and Research5 citations Open access
Semantic Scholar
The clinical utility of an mGPS and SII combined score in patients with advanced gastric cancer treated with nivolumab monotherapy
S. Udagawa, A. Ooki, H. Osumi, K. Yoshino +8 more
2025ESMO gastrointestinal oncology4 citations Open access
Semantic Scholar
Safety and efficacy of zolbetuximab plus chemotherapy for claudin 18 isoform 2-positive advanced gastric cancer: initial report of real-world experience
K. Shimozaki, A. Ooki, S. Fukuoka, H. Osumi +8 more
2025Journal of Cancer Research and Clinical Oncology4 citations Open access
Semantic Scholar
A phase Ib study of nivolumab plus trastuzumab with S-1/capecitabine plus oxaliplatin for HER2-positive advanced gastric cancer (Ni-HIGH study): Safety evaluation.
D. Takahari, H. Shoji, K. Minashi, H. Hara +11 more
20204 citations
Semantic Scholar
Real-world safety and efficacy of neoadjuvant docetaxel, cisplatin, and 5-fluorouracil therapy for locally advanced esophageal squamous cell carcinoma
M. Tamba, H. Osumi, M. Ogura, S. Fukuoka +11 more
2025BMC Cancer3 citations Open access
Semantic Scholar
Impact of early tumor shrinkage on survival outcomes in patients with HER2-positive advanced gastric cancer treated with trastuzumab deruxtecan in third- or later-line settings
K. Fukuda, H. Osumi, K. Shimozaki, K. Chin +9 more
2025Therapeutic Advances in Gastroenterology3 citations Open access
Semantic Scholar
Clinical outcomes and prognostic factors of concurrent chemoradiotherapy for anal squamous cell carcinoma in Japan
R. Takahashi, H. Osumi, T. Wakatsuki, Noriko Yamamoto +8 more
2024International Journal of Clinical Oncology3 citations Open access
Semantic Scholar
Impact of early tumor shrinkage and depth of response in patients with BRAF V600E-mutant metastatic colorectal cancer
Shohei Udagawa, H. Osumi, A. Ooki, K. Shimozaki +8 more
2024International Journal of Clinical Oncology3 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

K. Yamaguchi×37
Invite
K. Yamaguchi — researcher profile on SciRah
H. Osumi×33
Invite
H. Osumi — researcher profile on SciRah
E. Shinozaki×29
Invite
E. Shinozaki — researcher profile on SciRah
M. Ogura×28
Invite
M. Ogura — researcher profile on SciRah

×26

Invite

T. Wakatsuki — researcher profile on SciRah

D. Takahari×24

Invite

D. Takahari — researcher profile on SciRah

Invite

K. Chin — researcher profile on SciRah

I. Nakayama×23

Invite

I. Nakayama — researcher profile on SciRah

K. Shimozaki×17

Invite

K. Shimozaki — researcher profile on SciRah

Invite

S. Fukuoka — researcher profile on SciRah

D. Kamiimabeppu×10

Invite

D. Kamiimabeppu — researcher profile on SciRah

Invite

K. Yoshino — researcher profile on SciRah